# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-24-022723
Filing Date
2024-04-29
Accepted
2024-04-29 08:48:01
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | ny20022295x3_defa14a.htm | DEFA14A | 11473
2 |  | ny20022295x3_nc01.jpg | GRAPHIC | 517667
3 |  | ny20022295x3_nc02.jpg | GRAPHIC | 430589
| Complete submission text file | 0001140361-24-022723.txt |  | 1318230

Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-51173 | Film No.: 24886866
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)